MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc.…
Browsing Tag